Gennex Laboratories Share Price

Gennex Laboratories

CMP as on18-May-22 15:29

₹ 7.13
-0.21 -2.86%

Open

₹ 7.35

Turnover (lac)

₹ 37

Prev. Close

₹ 7.34

Day's Vol (shares)

₹ 2,39,886

Day's Range

₹ 7.00
₹ 7.59

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 28-Mar-2022 - -
GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/04/2022 inter alia to consider and approve With reference to the above captioned subject matter we hereby inform that a Meeting of Board of Directors of the Company will be held on Wednesday April 06 2022 at 12:00 Hrs at the Corporate Office of the Company inter-alia consider the following matters among other items of agenda: 1. To Consider the proposal for raising of funds by issuance of equity shares or any other securities through permissible modes including but not limited to a rights issue as may be permitted under applicable law and subject to such regulatory/ statutory approvals as may be required; 2. Other Business items. Pursuant to SEBI (Prohibition of insider Trading) Regulations 2015 the closure of trading window will end after 48 hours after the Outcome of the Meeting are made public. This intimation is also uploaded in the Company website: www.gennexlab.com. We request you to take note of the above information on record and acknowledge the receipt of the same. The Board of Directors at their meeting held today, approved the offer and issuance of fully paid-up equity shares of the Company (the Equity Shares) for an amount not exceeding Rs. 40 Crore (Rupees Forty Crore) by way of a rights issue to the eligible equity shareholders of the Company as on the record date (to be determined and notified subsequently), in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, subject to such approvals, as may be required under the applicable laws (Rights Issue). Board constituted Rights Issue Committee for the purposes of giving effect to the Rights Issue, the detailed terms in relation to the Rights Issue, including but not limiting to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course. The Board meeting commenced at 12:00 Hrs. and concluded at 12:25 Hrs. (As Per BSE Announcement Dated 06.04.2022)
Board Meeting - 07-Feb-2022 - -
GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 inter alia to consider and approve With reference to the above captioned subject matter we hereby inform you that the Meeting of Board of Directors of the Company will be held on Monday February 14 2022 at 04:00 PM at the Corporate Office of the Company inter-alia consider the following matters among other items of agenda: 1. Consider and adopt the Unaudited Financial Statements (Standalone and Consolidated) for the Quarter ended December 31 2021; 2. Consider the Limited Review Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Quarter ended December 31 2021; 3. Other Business items. Pursuant to SEBI (Prohibition of insider Trading) Regulations 2015 the closure of trading window will end after 48 hours after the results are made public. This intimation is also uploaded in the Company website: www.gennexlab.com. We request you to take note of the above information on record and acknowledge the receipt of the same. In just concluded Meeting of the Board Directors of the Company, the board has considered and approved: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine Months ended December 31, 2021 (annexed herewith); 2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine Months ended December 31, 2021 (annexed herewith). This intimation is also uploaded in the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge the receipt of the same. (As per BSE Announcement Dated on 14/02/2022) Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed herewith Newspaper Publication on Unaudited (Standalone & Consolidated) Financial results for the 03rd Quarter and Nine Months ended December 31, 2021 of our Company, which had been announced as outcome of the Board Meeting held on Monday, February 14, 2022, published in both Business Standard and Andhra Prabha on February 15, 2022. We request you to take the above information on record and acknowledge the receipt of the same (As Per BSE Announcement dated on 15.02.2022)
Board Meeting - 24-Dec-2021 - -
GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/01/2022 inter alia to consider and approve With reference to the above captioned subject matter we hereby inform the Stock Exchanges and Members of the Company that the Meeting of Board of Directors of the Company will be held on Tuesday January 04 2022 at 04:00 PM at the Corporate Office of the Company inter-alia consider the following matters among other items of agenda: 1. The Company is intending to make Deccan Remedies Limited (Deccan) as our subsidiary by acquire additional 836165 equity shares i.e. equivalent to 6.73% from the existing Deccan promoter group; 2. Proposing to Appoint Mr. Arihant Baid Managing Director of the Company in the Board of Deccan to manage the Affairs of Deccan. 3. Other Business items. This intimation is also uploaded in the Company website: www.gennexlab.com. We request you to take note of the above information on record and acknowledge the receipt of the same. In just concluded Meeting of the Board Directors of the Company, the board has considered and approved: 1. After through discussion on all the recommendations of the Audit Committee, board decided to make Deccan Remedies Limited (Deccan) as our Subsidiary Company by acquire additional 6.73% equity Shares i.e., 836,165 from the Existing promoter Shareholders group and in turn the Company will hold 51% equity shares of the Deccan. 2. Mr. Arihant Baid, Managing Director of the Company represent Gennex (the Company) in the Board of Deccan to manage the Affairs of the Deccan. (As per BSE Announcement Dated on 04/01/2022)
Board Meeting - 08-Nov-2021 - -
Quarterly Results In just concluded Meeting of the Board Directors of the Company, the board has considered and approved: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half Year ended September 30, 2021 (annexed herewith); 2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half Year ended September 30, 2021 (annexed herewith). This intimation is also uploaded in the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge the receipt of the same. (As Per BSE Announcement dated on 13.11.2021)
Board Meeting - 27-Aug-2021 - -
A.G.M. & Inter-alia, consider the following matters, among other items of agenda: 1. To decide regarding the conduct of 36th AGM for the year ended March 31, 2021; 2. To Consider the Appointment of Secretarial Auditor for the FY 2021-22; 3. To Consider the Appointment of Cost Auditor for the FY 2021-22. 4. To Consider and Appoint Scrutinizer of the 36th Annual General Meeting in case of Finalisation of the Date of AGM; 5. Other Business items. In the just concluded Meeting of Directors of the Company, the Board has considered and approved the matters pertains to conducting of 36th AGM and Notice Agenda items. This intimation is also uploaded in the Company website: www.gennexlab.com. We request you to take note of the above information on record and acknowledge the receipt of the same. With reference to the above captioned subject matter, we hereby inform you that the Board of Directors of the Company proposed to increase the Authorised Share Capital of the Company and Amendment to MOA & AOA of the Company in line with the Companies Act, 2013, subject to the approval of the Members to be held 36th AGM of the Company. In this regard, please find the attached Intimation/Disclosure under Reg.30 of SEBI (LODR) Regulations, 2015 for your perusal. The above proposed items are considered in the Board Meeting held today and the same was mentioned in the outcome of the Meeting submitted to the Exchange. Please acknowledge the same. (As Per BSE Announcement dated on 06.09.2021)
Board Meeting - 05-Aug-2021 - -
Quarterly Results Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed herewith Newspaper Publication on Meeting of the Board Directors of the Company Scheduled to be held on Friday, August 13, 2021 for the adoption of Unaudited (Standalone & Consolidated) Financial Results for the quarter ended June 30, 2021. Notice had been published in both Business Standard and Andhra Prabha on August 06, 2021. We request you to take the above information on record and acknowledge the receipt of the same. Pursuant to provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. August 13, 2021, inter-alia, considered the following business: 1. Approved the unaudited Standalone & Consolidated Financial results of the Company for the quarter ended June 30, 2021, prepared in accordance with the Indian Accounting Standards (Ind AS) as per Companies (Indian Accounting Standard) Rules, 2015. 2. The Company intends to raise funds by Rights Issue/preferential allotment for the purpose of long-term Working Capital and Extension of Production lines in this regard. The Company has appointed SEBI registered Merchant Banker. We request you to take note of the above information on record and acknowledge the receipt of the same. Pursuant to provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. August 13, 2021, inter-alia, considered the following business: 1. Approved the unaudited Standalone & Consolidated Financial results of the Company for the quarter ended June 30, 2021, prepared in accordance with the Indian Accounting Standards (Ind AS) as per Companies (Indian Accounting Standard) Rules, 2015 along with the Limited review report of the Statutory Auditor. We request you to take note of the above information on record and acknowledge the receipt of the same. (As per BSE Announcement Dated on 13/8/2021)
Board Meeting - 21-Jun-2021 - -
GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/06/2021 ,inter alia, to consider and approve With reference to the above captioned subject matter, pursuant to the referred regulations of SEBI (LODR) Regulations, 2015 mentioned above, we hereby inform you that the Meeting of the Board of Directors of the Company will be held on Wednesday, June 30, 2021, at the Corporate Office of the Company, inter-alia, to consider the following matters: 1. Consider and adopt the Audited Financial Statements (Standalone and Consolidated) for the Quarter and Year ended March 31, 2021; 2. Consider the Independent Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Quarter and Year ended March 31, 2021. 3. Other Business items. This intimation is also being uploaded in the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge the receipt of the same. In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1.Audited Standalone & Consolidated Financial results for the quarter ended & Year Ended March 31, 2021, 2.Auditors Report on audited Standalone & Consolidated Financial Statements for the Quarter and Year ended March 31, 2021, issued on dated June 30, 2020 along with Form - B are attached herewith - Annexure I; We request you to take note of the above information on record and acknowledge the receipt of the same. (As Per BSE Announcement Dated on 30/06/2021)
Board Meeting - 11-Jun-2021 - -
GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/06/2021 ,inter alia, to consider and approve With reference to the above captioned subject matter, we hereby inform you that the Meeting of Board of Directors of the Company will be held on Friday, June 18, 2021 at the Corporate Office of the Company, inter-alia, to consider the following matters: 1.Appointment of Mr. Rakesh Kumar Gupta as a Secretarial Auditor of the Company for the Financial Year 2020-21; 2.Other Business items. This intimation is also being uploaded in the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge the receipt of the same. In the just concluded Meeting of the Board Directors of the Company, the board has considered and approved: 1. Appointment of Mr. Rakesh Kumar Gupta, Practicing Company Secretary, as the Secretarial Auditor of the Company for the Financial Year 2020-21; 2. Reconstitution of Audit Committee of the Company. This intimation is also uploaded in the Company website: www.gennexlab.com. (As Per BSE Announcement Dated 18.06.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity